Literature DB >> 17461443

Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005).

Rui Tato Marinho1, José Giria, Miguel Carneiro Moura.   

Abstract

AIM: To determine, for hepatocellular carcinoma (HCC), the patient demographic profile and costs of their admissions to the hospitals of the Portuguese National Health System from 1993 to 2005.
METHODS: The National Registry (ICD-9CM, Inter-national Classification of Diseases, 155.0) provided data from the 97 Hospitals in Portugal.
RESULTS: We studied 7932 admissions that progressively rose from 292 in 1993 to 834 in 2005, having a male predominance of 78% (6130/7932). The global rate of hospital admissions for HCC rose from 3.1/10(5) in 1993 to 8.3/10(5) in 2005. The average length of stay decreased from 17.5 +/- 17.9 d in 1993 to 9.3 +/- 10.4 d in 2005, P < 0.001. The average hospital mortality for HCC remained high over these years, 22.3% in 1993 and 26.7% in 2005. Nationally, hospital costs (in Euros - EUR) rose in all variables studied: overall costs from 533,000 Euros in 1993, to 462,9000 Euros in 2005, cost per day of stay from 105 Euros in 1993, to 597 Euros in 2005, average cost of each admission from 1828 Euros in 1993, to 5550 Euros in 2005. In 2005, 1.8% (15/834) of hospital admissions for HCC were related to liver transplant, and responsible for a cost of about 1.5 million Euros, corresponding to one third of the overall costs for HCC admissions in that same year.
CONCLUSION: From 1993 to 2005 hospital admissions in Portugal for HCC tripled. Overall costs for these admissions increased 9 times, with all variables related to cost analysis rising accordingly. Liver transplant, indicated in a small group of patients, showed a disproportionate increase in costs.

Entities:  

Mesh:

Year:  2007        PMID: 17461443      PMCID: PMC4146893          DOI: 10.3748/wjg.v13.i10.1522

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  37 in total

Review 1.  Hepatocellular carcinoma: present status and future prospects.

Authors:  Josep M Llovet; Michel Beaugrand
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

2.  Burden of liver disease in the United States: summary of a workshop.

Authors:  W Ray Kim; Robert S Brown; Norah A Terrault; Hashem El-Serag
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

3.  Data quality of administratively collected hospital discharge data for liver cirrhosis epidemiology.

Authors:  K Vestberg; A M Thulstrup; H T Sørensen; P Ottesen; S Sabroe; H Vilstrup
Journal:  J Med Syst       Date:  1997-02       Impact factor: 4.460

Review 4.  Transplantation for hepatocellular carcinoma: The Milan criteria and beyond.

Authors:  Richard B Freeman
Journal:  Liver Transpl       Date:  2006-11       Impact factor: 5.799

5.  A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma.

Authors:  F Donato; P Boffetta; M Puoti
Journal:  Int J Cancer       Date:  1998-01-30       Impact factor: 7.396

6.  Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.

Authors:  M Chiaramonte; T Stroffolini; A Vian; M A Stazi; A Floreani; U Lorenzoni; S Lobello; F Farinati; R Naccarato
Journal:  Cancer       Date:  1999-05-15       Impact factor: 6.860

7.  Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe.

Authors:  S Deuffic; T Poynard; A J Valleron
Journal:  J Viral Hepat       Date:  1999-09       Impact factor: 3.728

8.  Effect of patient characteristics on hospital costs for cirrhosis: implications for the disease-related group (DRG) reimbursement system.

Authors:  F Rosina; P Alaria; S Castelli; N Dirindin; G Rocca; G C Actis; R Borelli; A L Ciancio; W De Bernardi; S Fornasiero; B Lavezzo; M Lagget; R Martinotti; A Marzano; A Ottobrelli; R Sostegni; M Rizzetto; G Verme
Journal:  Ital J Gastroenterol       Date:  1996-09

9.  The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States.

Authors:  K Kulkarni; E Barcak; H El-Serag; R Goodgame
Journal:  Aliment Pharmacol Ther       Date:  2004-08-15       Impact factor: 8.171

10.  Risk factors for hepatocellular carcinoma in Italy. Male sex, hepatitis B virus, non-A non-B infection, and alcohol.

Authors:  E Villa; G M Baldini; C Pasquinelli; M Melegari; E Cariani; G Di Chirico; F Manenti
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

View more
  6 in total

1.  Sorafenib Improves Survival in Metastatic Hepatocellular Carcinoma: A Case Report.

Authors:  Filipe Nery; Luis Graca; Manuel Ribeiro; Henrique Guimaraes; Helena Pessegueiro Miranda
Journal:  World J Oncol       Date:  2010-11-02

2.  Mortality Associated with Hepatobiliary Disease in Portugal between 2006 and 2012.

Authors:  Manuel Coelho da Rocha; Rui T Marinho; Teresa Rodrigues
Journal:  GE Port J Gastroenterol       Date:  2017-12-06

3.  Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers.

Authors:  Giorgio Lorenzo Colombo; Calogero Cammà; Adolfo Francesco Attili; Roberto Ganga; Giovanni Battista Gaeta; Giuseppina Brancaccio; Jean Marie Franzini; Marco Volpe; Giuseppe Turchetti
Journal:  Ther Clin Risk Manag       Date:  2015-10-19       Impact factor: 2.423

4.  An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal.

Authors:  Sofia Vitor; Rui Tato Marinho; José Gíria; José Velosa
Journal:  BMC Res Notes       Date:  2016-02-03

5.  Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score.

Authors:  Pedro Magalhães-Costa; Luís Lebre; Paula Peixe; Sofia Santos; Cristina Chagas
Journal:  GE Port J Gastroenterol       Date:  2016-04-05

6.  Hepatocellular Carcinoma: Portuguese Data in Chronic Hepatitis B Patients on Antiviral Therapy and Treatment Results With Sorafenib.

Authors:  Adélia Simão
Journal:  GE Port J Gastroenterol       Date:  2016-09-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.